Page 36 - Read Online

Agresti et al. J Transl Genet Genom 2018;2:9 I http://dx.doi.org/10.20517/jtgg.2018.05 Page 11 of 11

44. Karicheva OZ, Kolesnikova OA, Schirtz T, Vysokikh MY, Mager-Heckel AM, Lombes A, Boucheham A, Krasheninnikov IA, Martin
RP, Entelis N, Tarassov I. Correction of the consequences of mitochondrial 3243A>G mutation in the MT-TL1 gene causing the
MELAS syndrome by tRNA import into mitochondria. Nucleic Acids Res 2011;39:8173-86.
45. Sasarman F, Antonicka H, Shoubridge EA. The A3243G tRNALeu(UUR) MELAS mutation causes amino acid misincorporation and a
combined respiratory chain assembly defect partially suppressed by overexpression of EFTu and EFG2. Hum Mol Genet 2008;17:3697-
707.
46. Park H, Davidson E, King MP. Overexpressed mitochondrial leucyl-tRNA synthetase suppresses the A3243G mutation in the
mitochondrial tRNA(Leu(UUR)) gene. RNA 2008;14:2407-16.
47. Li R, Guan MX. Human mitochondrial leucyl-tRNA synthetase corrects mitochondrial dysfunctions due to the tRNALeu(UUR)
A3243G mutation, associated with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like symptoms and diabetes. Mol Cell
Biol 2010;30:2147-54.
48. Perli E, Giordano C, Pisano A, Montanari A, Campese AF, Reyes A, Ghezzi D, Nasca A, Tuppen HA, Orlandi M, Di Micco P, Poser
E, Taylor RW, Colotti G, Francisci S, Morea V, Frontali L, Zeviani M, d’Amati G. The isolated carboxy-terminal domain of human
mitochondrial leucyl-tRNA synthetase rescues the pathological phenotype of mitochondrial tRNA mutations in human cells. EMBO
Mol Med 2014;6:169-82.
49. Perli E, Fiorillo A, Giordano C, Pisano A, Montanari A, Grazioli P, Campese AF, Di Micco P, Tuppen HA, Genovese I, Poser E, Preziuso
C, Taylor RW, Morea V, Colotti G, d’Amati G. Short peptides from leucyl-tRNA synthetase rescue disease-causing mitochondrial tRNA
point mutations. Hum Mol Genet 2016;25:903-15.
50. Chang JC, Liu KH, Chuang CS, Su HL, Wei YH, Kuo SJ, Liu CS. Treatment of human cells derived from MERRF syndrome by
peptide-mediated mitochondrial delivery. Cytotherapy 2013;15:1580-96.
51. Chang JC, Liu KH, Li YC, Kou SJ, Wei YH, Chuang CS, Hsieh M, Liu CS. Functional recovery of human cells harbouring the
mitochondrial DNA mutation MERRF A8344G via peptide-mediated mitochondrial delivery. Neurosignals 2013;21:160-73.
52. Chang JC, Hoel F, Liu KH, Wei YH, Cheng FC, Kuo SJ, Tronstad KJ, Liu CS. Peptide-mediated delivery of donor mitochondria
improves mitochondrial function and cell viability in human cybrid cells with the MELAS A3243G mutation. Sci Rep 2017;7:10710.
53. Muratovska A, Lightowlers RN, Taylor RW, Turnbull DM, Smith RA, Wilce JA, Martin SW, Murphy MP. Targeting peptide nucleic
acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: implications for mitochondrial DNA replication,
expression and disease. Nucleic Acids Res 2001;29:1852-63.
54. Taylor RW, Chinnery PF, Turnbull DM, Lightowlers RN. Selective inhibition of mutant human mitochondrial DNA replication in vitro
by peptide nucleic acids. Nat Genet 1997;15:212-5.
55. Bacman SR, Hashimoto M, Peralta S, Falk MJ, Chomyn A, Chan DC, Williams SL, Moraes CT. mitoTALENs as DNA editing tools for
mitochondrial diseases. Mitochondrion 2015;24:S22.
56. Hashimoto M, Bacman SR, Peralta S, Falk MJ, Chomyn A, Chan DC, Williams SL, Moraes CT. MitoTALEN: a general approach to
reduce mutant mtDNA loads and restore oxidative phosphorylation function in mitochondrial diseases. Mol Ther 2015;23:1592-9.